Dr. Dickstein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
7580 Buckingham Blvd
Suite 110
Hanover, MD 21076Phone+1 410-760-9400Fax+1 410-787-1911
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Urologic Surgical Oncology, 2010 - 2012
Boston University Medical CenterResidency, Urology, 2006 - 2010- Boston University Medical CenterInternship, Transitional Year, 2005 - 2006
Rutgers Robert Wood Johnson Medical SchoolClass of 2005
Certifications & Licensure
MD State Medical License 2012 - 2026
TX State Medical License 2010 - 2014- American Board of Urology Urology
Publications & Presentations
PubMed
- 3 citationsOncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua
Nature Medicine. 2024-08-01 - 1 citationsStandardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials.Yair Lotan, Piyush Agarwal, Peter Black, Rian Dickstein, Ashish M Kamat
Urologic Oncology. 2024-08-01 - 34 citationsClinical risk stratification in patients with surgically resectable micropapillary bladder cancerMario I. Fernández, Stephen B. Williams, Daniel L. Willis, Rebecca Slack, Rian J. Dickstein
BJU International. 2017-05-01
Press Mentions
UMMS in the NewsApril 15th, 2021
Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer Achieves 42% Complete Response Rate at Three Months in Carcinoma in Situ PatientsMay 21st, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
